Obesity is a chronic disease often encompassed by a multitude of serious comorbidities, making its prevention and treatment public health priorities. Globally, by 2030, the numbers of adults who are overweight ( It has been shown that an increase in BMI is directly correlated with a reduction in life expectancy and increase in obesity-related comorbidities such as type 2 diabetes mellitus (T2DM).3-5 A 5-10% weight loss can provide clinically relevant improvements in obesity-related comorbidities and quality of life (QoL).6,7 Depending on BMI classification and the number/severity of comorbidities, behavioral therapy including dietary and physical activity changes, pharmacotherapy and (in the appropriate patient) bariatric surgery are recommended. 8,9 However, achieving and maintaining weight loss by diet and physical activity alone can be challenging.10-12 Pharmacotherapy supports weight loss and Background: Obesity is associated with multiple comorbidities and increased mortality, making it an important target for treatment. However, achieving and maintaining weight loss by diet and physical activity remains challenging, and may often require pharmacotherapy. Liraglutide 3.0 mg has recently been approved for weight management in the United States, Canada, and EU. The current analysis used a summative usability test to assess safety and effectiveness, ease of use, and training requirements for the novel liraglutide 3.0 mg pen injector.